Drug-Induced Liver Injury 

|

Drug-Induced Liver Injury
Why DILI Idiosyncrasy? The Immune System and Beyond ...

March 14-15, 2012
National Labor College
10000 New Hampshire Avenue at Powder Mill Road
Silver Spring, MD 20903

• Food and Drug Administration/Center for Drug Evaluation and Research (FDA/CDER),
• National Institutes of Health (NIH) Drug-induced Liver Injury Network (DILIN),
• Pharmaceutical Research and Manufacturers of America (PhRMA)

Organizers:
John R. Senior, MD and Lana Pauls, MPH

Advisors:
Mark Avigan, MD, CM; Robert Fontana, MD; Christine Hunt, MD; Michael Merz, MD; Arie Regev, MD; Leonard Seeff, MD; and Paul Watkins, MD

Why DILI Idiosyncrasy? The Immune System and Beyond ...
Why Do Only A Few People Show Serious Liver Dysfunction
From Drugs That Nearly Everybody Else Can Tolerate or Adapt To?

DILI is still a major problem for drug development, and a clinical concern after marketing. We need new biomarkers, new understanding, and a path forward to solve the problems. This academic-industry-government international conference will discuss new findings and thinking about drug-induced liver injury (DILI), including presentations by experts in clinical hepatology, toxicology, and other fields, and discussion with all registrants. Come and participate in this conference.

Meeting Agenda and Registration coming soon.